Making medicines available to patients who need them is one of the obligations ensuing from Our Credo. This is chiefly a major challenge in remote areas such as Africa where the distribution channels are inadequate. In numerous remote areas, every day people succumb to diseases for which simple remedies already exist. The medicines do exist, but they do not get to the patients. Today 20% of children die an avoidable death caused by diseases such as diarrhea.

A two-year pilot project Health2Wealth from the NGO ColaLife, with support from Johnson & Johnson, has been taking place in Zambia since the autumn of 2012. Anti-diarrhea medicines are packaged to perfectly fit between the Cola bottles in a crate. No mass-produced product has succeeded better in reaching the remotest corners of the world than Coca-Cola.

Each crate contains bags of rehydration salt, a box of zinc tablets and a piece of soap. The packaging has the form of a drinking beaker in which the salt can be dissolved in the correct amount of water while the lid keeps dirt and flies away. The original Yamoyo anti-diarrhea kit won different prizes, including the Product Design of the Year 2013 Award.

.

Colalife_bak_10cm.jpg

Kit Yamoyo features

Up until a year ago African mothers had to walk kilometers to fetch medicines for their sick children. Now in Zambia there are trained micro-distributors who make the kits available at different locations close to residential areas. BY the end of 2013 ColaLife had distributed more than 25,000 anti-diarrhea kits in two Zambian districts. This would appear to be a simple remedy, but it has a valuable impact on the local population. The dream is to also be able to use this packaging to fight other diseases such as diabetes and HIV/AIDS. Everything is being done to get medicines closer and more quickly to the people. 

Durabilité
Économique

Janssen believes that strong corporate results, correct policies and focused activities pave the way towards economic sustainability. 

Janssen must constantly reinvent itself in order to cope with the structural and economic changes that affect its environment. This is why Janssen is committed to build partnerships within an open innovation model, and to the continuous alignment of its cost-competitiveness by only developing medicines with a high therapeutic added value. 

For Janssen this means specifically: being focused and a leader in research & development, and being efficient and progressive in terms of production with the aim of bringing new therapeutic solutions to patients quicker and at less expense, and implementing a growth strategy to ensure our continued investment in all these areas.